These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Depo Provera. Position paper on clinical use, effectiveness and side effects. Bigrigg A, Evans M, Gbolade B, Newton J, Pollard L, Szarewski A, Thomas C, Walling M. Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658 [Abstract] [Full Text] [Related]
6. Researchers can now investigate long-term effects of OCs on cancer. Rubin GL, Peterson HB. Contracept Technol Update; 1985 Jan; 6(1):7-12. PubMed ID: 12279918 [Abstract] [Full Text] [Related]
7. Demographic analysis of post-abortive and interval-administered hormonal contraceptive methods. Ertopçu K, Inal MM, Ozelmas I. Eur J Contracept Reprod Health Care; 2005 Mar; 10(1):1-5. PubMed ID: 16036290 [Abstract] [Full Text] [Related]
9. The Royal College of General Practitioners' Oral Contraception Study: some recent observations. Kay CR. Clin Obstet Gynaecol; 1984 Dec; 11(3):759-86. PubMed ID: 6509858 [Abstract] [Full Text] [Related]
11. Breast cancer and depot-medroxyprogesterone acetate. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Thomas DB, Noonan L, Whitehead A. Bull World Health Organ; 1985 Dec; 63(3):513-9. PubMed ID: 2931206 [Abstract] [Full Text] [Related]
16. Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population. Polaneczky M, Guarnaccia M, Alon J, Wiley J. Fam Plann Perspect; 1996 Dec; 28(4):174-8. PubMed ID: 8853283 [Abstract] [Full Text] [Related]
17. Bone mineral density and depot medroxyprogesterone acetate. Albertazzi P, Bottazzi M, Steel SA. Contraception; 2006 Jun; 73(6):577-83. PubMed ID: 16730487 [Abstract] [Full Text] [Related]